{"id":"part-b","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5095427","moleculeType":"Gene"},"_fixedAt":"2026-03-30T13:32:19.466605","_dailymed":{"setId":"68e1ab6b-7dfd-4306-9e3e-021fe330519c","title":"COVER ALL MAX PART B (SODIUM CHLORITE) SOLUTION [COVER ALL MAX PART B]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This appears to be a misidentification. 'Part B' is not a drug name but rather a component of the U.S. Medicare insurance system that covers physician services, outpatient care, and durable medical equipment. There is no marketed pharmaceutical drug by this name from GlaxoSmithKline.","oneSentence":"Part B refers to Medicare Part B, which is a government insurance program, not a pharmaceutical drug.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:59:50.976Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"_fixedFields":["pubmed(5334)"],"trialDetails":[{"nctId":"NCT07155174","phase":"PHASE2","title":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-25","conditions":"Small Cell Lung Cancer","enrollment":180},{"nctId":"NCT07161011","phase":"PHASE2","title":"Phase 2b Controlled Study of Dosing Techniques - Part B","status":"COMPLETED","sponsor":"IVIEW Therapeutics Inc.","startDate":"2025-09-08","conditions":"Dry Eye","enrollment":15},{"nctId":"NCT05768932","phase":"PHASE1","title":"BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"SillaJen, Inc.","startDate":"2022-12-14","conditions":"Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer","enrollment":260},{"nctId":"NCT07396584","phase":"PHASE1, PHASE2","title":"HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor","status":"RECRUITING","sponsor":"Hutchmed","startDate":"2026-03-04","conditions":"Solid Tumors, Adult","enrollment":186},{"nctId":"NCT07450833","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers","status":"COMPLETED","sponsor":"Benfovir AG","startDate":"2022-03-01","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT07498374","phase":"NA","title":"Efficacy and Safety of Fully Resorbable Sinus Drug-eluting Stents in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps After Surgery: A Prospective, Randomized Controlled Trial","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2026-01-21","conditions":"Eosinophilic Chronic Rhinosinusitis With Nasal Polyps","enrollment":192},{"nctId":"NCT00268385","phase":"PHASE1","title":"Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-12-16","conditions":"Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma","enrollment":83},{"nctId":"NCT06498648","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-18","conditions":"Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma","enrollment":74},{"nctId":"NCT07113743","phase":"PHASE1, PHASE2","title":"Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-10","conditions":"Chronic Granulomatous Disease (CGD)","enrollment":10},{"nctId":"NCT07220785","phase":"PHASE3","title":"Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-13","conditions":"Generalized Lipodystrophy","enrollment":28},{"nctId":"NCT05131022","phase":"PHASE1","title":"A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies","status":"RECRUITING","sponsor":"Nurix Therapeutics, Inc.","startDate":"2022-04-13","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":572},{"nctId":"NCT05531565","phase":"PHASE2, PHASE3","title":"A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"Biogen","startDate":"2022-09-13","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":450},{"nctId":"NCT06858579","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)","status":"RECRUITING","sponsor":"Dianthus Therapeutics","startDate":"2025-02-10","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":480},{"nctId":"NCT04849728","phase":"PHASE3","title":"A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventiva Pharma","startDate":"2021-08-19","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":1000},{"nctId":"NCT06980428","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-27","conditions":"Healthy Participants, Dyslipidemia","enrollment":136},{"nctId":"NCT06945419","phase":"PHASE1","title":"A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-04-23","conditions":"Healthy, Overweight, Obesity","enrollment":216},{"nctId":"NCT05753501","phase":"PHASE1","title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-09","conditions":"Hematologic Cancer","enrollment":135},{"nctId":"NCT06628310","phase":"PHASE2","title":"A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-12-13","conditions":"Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":180},{"nctId":"NCT05020236","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-10-04","conditions":"Multiple Myeloma","enrollment":944},{"nctId":"NCT06561685","phase":"PHASE1","title":"A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-09-19","conditions":"Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer","enrollment":340},{"nctId":"NCT05012033","phase":"","title":"Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2023-04-12","conditions":"Thyroid Eye Disease, Vasculitis, COPD Exacerbation Acute","enrollment":120},{"nctId":"NCT06385119","phase":"PHASE1","title":"A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.","status":"COMPLETED","sponsor":"Fore Biotherapeutics","startDate":"2024-04-24","conditions":"Healthy Participants","enrollment":28},{"nctId":"NCT07022119","phase":"PHASE1","title":"A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-06-12","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":32},{"nctId":"NCT07446855","phase":"PHASE1, PHASE2","title":"Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-17","conditions":"Solid Tumours","enrollment":180},{"nctId":"NCT04482309","phase":"PHASE2","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-08-18","conditions":"Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer","enrollment":477},{"nctId":"NCT05307705","phase":"PHASE1","title":"A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-05-11","conditions":"Breast Cancer","enrollment":193},{"nctId":"NCT06582199","phase":"NA","title":"Precision Medicine in Alzheimer's Disease : Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-10-31","conditions":"Alzheimer Disease","enrollment":244},{"nctId":"NCT07498478","phase":"PHASE2","title":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","status":"RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2026-03-17","conditions":"Breast Cancer","enrollment":94},{"nctId":"NCT06507904","phase":"PHASE1","title":"A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-09-15","conditions":"Healthy","enrollment":52},{"nctId":"NCT06657768","phase":"PHASE1","title":"A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-29","conditions":"Alzheimer Disease, Healthy","enrollment":128},{"nctId":"NCT04234113","phase":"PHASE1","title":"Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors","status":"TERMINATED","sponsor":"SOTIO Biotech AG","startDate":"2019-06-13","conditions":"Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer","enrollment":115},{"nctId":"NCT06637371","phase":"PHASE1","title":"A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-10-16","conditions":"Asthma","enrollment":124},{"nctId":"NCT07326566","phase":"PHASE2","title":"Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII","status":"RECRUITING","sponsor":"Black Diamond Therapeutics, Inc.","startDate":"2026-04","conditions":"Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM","enrollment":162},{"nctId":"NCT05286801","phase":"PHASE1, PHASE2","title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-17","conditions":"Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma","enrollment":86},{"nctId":"NCT07497724","phase":"","title":"Retrospective Observational Study of Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC)","status":"NOT_YET_RECRUITING","sponsor":"Ipsen","startDate":"2026-04-01","conditions":"PFIC - Progressive Familial Intrahepatic Cholestasis","enrollment":200},{"nctId":"NCT07496229","phase":"PHASE1, PHASE2","title":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","status":"NOT_YET_RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2026-03","conditions":"T-cell Lymphomas","enrollment":165},{"nctId":"NCT06033209","phase":"PHASE1","title":"A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-11-27","conditions":"HIV","enrollment":57},{"nctId":"NCT04277637","phase":"PHASE1","title":"Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2020-03-24","conditions":"Mature B-Cell Malignancies","enrollment":437},{"nctId":"NCT06154447","phase":"PHASE1","title":"Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-12-12","conditions":"Cystic Fibrosis","enrollment":255},{"nctId":"NCT06630806","phase":"PHASE1","title":"A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-10-30","conditions":"Plasma Cell Myeloma Refractory","enrollment":87},{"nctId":"NCT04670679","phase":"PHASE1","title":"A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasca, Inc.","startDate":"2020-12-15","conditions":"Advanced or Metastatic Solid Tumors","enrollment":90},{"nctId":"NCT06788756","phase":"PHASE2, PHASE3","title":"L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML","status":"RECRUITING","sponsor":"Moleculin Biotech, Inc.","startDate":"2025-03-12","conditions":"Acute Myeloid Leukaemia (AML)","enrollment":312},{"nctId":"NCT06166836","phase":"PHASE1, PHASE2","title":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2022-10-12","conditions":"Solid Tumor","enrollment":140},{"nctId":"NCT07491848","phase":"","title":"Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D","status":"RECRUITING","sponsor":"Research Center of Periodontal-Systemic Interactions","startDate":"2026-02-15","conditions":"HEPATITIS B CHRONIC, Hepatitis D, Periodontitis","enrollment":25},{"nctId":"NCT07492355","phase":"PHASE1","title":"TP-3654 Food Effect Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2024-03-04","conditions":"Myelofibroses","enrollment":24},{"nctId":"NCT04534205","phase":"PHASE2, PHASE3","title":"A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2021-01-07","conditions":"Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer","enrollment":350},{"nctId":"NCT07250048","phase":"PHASE1","title":"A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2025-11-21","conditions":"Healthy","enrollment":40},{"nctId":"NCT06119581","phase":"PHASE3","title":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-12-21","conditions":"Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis","enrollment":1264},{"nctId":"NCT07489599","phase":"PHASE1","title":"A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)","enrollment":68},{"nctId":"NCT07491094","phase":"","title":"Repeated Examinations for Typing Pulmonary Embolism","status":"NOT_YET_RECRUITING","sponsor":"Sahlgrenska University Hospital","startDate":"2026-04-01","conditions":"Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute, Pulmonary Embolism With Acute Cor Pulmonale","enrollment":400},{"nctId":"NCT05312879","phase":"PHASE2, PHASE3","title":"Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-03-30","conditions":"Proteinuric Kidney Disease","enrollment":466},{"nctId":"NCT05936359","phase":"PHASE1","title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-09-25","conditions":"Myeloproliferative Neoplasms","enrollment":225},{"nctId":"NCT02881320","phase":"PHASE2, PHASE3","title":"Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2016-09-21","conditions":"HIV-1 Infection","enrollment":177},{"nctId":"NCT07490301","phase":"PHASE2, PHASE3","title":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"AbbVie","startDate":"2026-06-03","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, PDAC","enrollment":900},{"nctId":"NCT07095452","phase":"PHASE2, PHASE3","title":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","status":"RECRUITING","sponsor":"AbbVie","startDate":"2026-01-08","conditions":"Multiple Myeloma","enrollment":660},{"nctId":"NCT04995523","phase":"PHASE1, PHASE2","title":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-09-14","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":212},{"nctId":"NCT07160725","phase":"PHASE1, PHASE2","title":"A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-10-15","conditions":"Solid Tumours","enrollment":315},{"nctId":"NCT06884865","phase":"PHASE2","title":"A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pacira Pharmaceuticals, Inc","startDate":"2025-02-26","conditions":"Osteoarthritis (OA) of the Knee","enrollment":135},{"nctId":"NCT04082429","phase":"PHASE3","title":"Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2019-11-13","conditions":"Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors","enrollment":156},{"nctId":"NCT06890598","phase":"PHASE3","title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":700},{"nctId":"NCT04384484","phase":"PHASE3","title":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ADC Therapeutics S.A.","startDate":"2020-09-16","conditions":"Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":440},{"nctId":"NCT06430385","phase":"PHASE1, PHASE2","title":"ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)","status":"RECRUITING","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2024-10-21","conditions":"Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome","enrollment":48},{"nctId":"NCT04083781","phase":"PHASE3","title":"Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2019-10-21","conditions":"Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":134},{"nctId":"NCT07412691","phase":"PHASE1","title":"A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2026-03-19","conditions":"Skin Diseases","enrollment":98},{"nctId":"NCT06862453","phase":"PHASE1","title":"Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults","status":"NOT_YET_RECRUITING","sponsor":"Sanaria Inc.","startDate":"2026-03","conditions":"Malaria Falciparum","enrollment":58},{"nctId":"NCT06748053","phase":"PHASE2","title":"A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-02-10","conditions":"Asthma","enrollment":307},{"nctId":"NCT07488897","phase":"PHASE1, PHASE2","title":"RIG 101 Trial in Healthy Adults and Adults With Asthma","status":"RECRUITING","sponsor":"RIGImmune Inc.","startDate":"2026-02-09","conditions":"Healthy Adult Participants, Asthma Exacerbation, Safety and Efficacy","enrollment":82},{"nctId":"NCT07059494","phase":"PHASE4","title":"Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-06","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT07276958","phase":"PHASE1","title":"A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-04","conditions":"Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis","enrollment":63},{"nctId":"NCT07489066","phase":"PHASE2","title":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-04-01","conditions":"Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC)","enrollment":120},{"nctId":"NCT05123482","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-18","conditions":"Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer","enrollment":460},{"nctId":"NCT07012395","phase":"PHASE2","title":"A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Spyre Therapeutics, Inc.","startDate":"2025-05-27","conditions":"Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis","enrollment":645},{"nctId":"NCT07325292","phase":"PHASE3","title":"Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-14","conditions":"Multiple Sclerosis","enrollment":160},{"nctId":"NCT07103018","phase":"PHASE1","title":"A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)","status":"RECRUITING","sponsor":"K36 Therapeutics, Inc.","startDate":"2025-11-21","conditions":"Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC","enrollment":144},{"nctId":"NCT05992935","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-08-25","conditions":"Norovirus Acute Gastroenteritis","enrollment":1405},{"nctId":"NCT03997786","phase":"PHASE2, PHASE3","title":"A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-01-15","conditions":"Moderate-to-severe Chronic Plaque Psoriasis","enrollment":135},{"nctId":"NCT07041099","phase":"PHASE1","title":"A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease","status":"RECRUITING","sponsor":"Cullinan Therapeutics Inc.","startDate":"2025-10-01","conditions":"Sjögren, Sjogren Disease, Sjogren's Syndrome","enrollment":36},{"nctId":"NCT07235059","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-11-20","conditions":"Chronic Kidney Disease","enrollment":112},{"nctId":"NCT07005102","phase":"PHASE2, PHASE3","title":"A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-08-03","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":854},{"nctId":"NCT06896916","phase":"PHASE1","title":"Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-08-07","conditions":"Multiple Myeloma","enrollment":135},{"nctId":"NCT06698575","phase":"PHASE1","title":"A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2024-12-08","conditions":"Recurrent Genital Herpes Simplex Type 2","enrollment":103},{"nctId":"NCT06132893","phase":"PHASE2, PHASE3","title":"A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy","status":"RECRUITING","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2024-03-14","conditions":"Focal Epilepsy","enrollment":390},{"nctId":"NCT07215234","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-10-09","conditions":"Geographic Atrophy","enrollment":104},{"nctId":"NCT06789081","phase":"EARLY_PHASE1","title":"GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2024-02-01","conditions":"Alveolar Soft Part Sarcoma","enrollment":1},{"nctId":"NCT02503423","phase":"PHASE1, PHASE2","title":"Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2015-07-14","conditions":"Solid Tumors, Lymphoma","enrollment":253},{"nctId":"NCT02773030","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":"Multiple Myeloma","enrollment":466},{"nctId":"NCT06869018","phase":"PHASE1","title":"A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2025-05-07","conditions":"Healthy, Type 2 Diabetes Mellitus (T2D)","enrollment":92},{"nctId":"NCT06994468","phase":"NA","title":"Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2025-09-22","conditions":"Membranous Nephropathy","enrollment":48},{"nctId":"NCT06641908","phase":"PHASE1","title":"Anti-GD2 ADC M3554 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2024-11-08","conditions":"Advanced Solid Tumor","enrollment":52},{"nctId":"NCT07449390","phase":"PHASE1","title":"Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole","status":"NOT_YET_RECRUITING","sponsor":"Acesion Pharma","startDate":"2026-04-22","conditions":"Healthy Participants","enrollment":28},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT05431088","phase":"PHASE2, PHASE3","title":"A Phase 2/3 Study in Adult and Adolescent Participants With SCD","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-09-22","conditions":"Sickle Cell Disease","enrollment":389},{"nctId":"NCT06462235","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-09-25","conditions":"Gram-negative Bacterial Infection","enrollment":48},{"nctId":"NCT06379789","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-11","conditions":"Hemophilia B","enrollment":130},{"nctId":"NCT06831955","phase":"PHASE2","title":"LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-02-01","conditions":"Triple Negative Breast Cancer (TNBC), Early Setting","enrollment":356},{"nctId":"NCT07486089","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)","enrollment":60},{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT05623020","phase":"PHASE3","title":"A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-11-10","conditions":"Multiple Myeloma","enrollment":1116},{"nctId":"NCT05039801","phase":"PHASE1","title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-09","conditions":"Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5334,"recentPublications":[{"date":"2026 Mar 28","pmid":"41904192","title":"Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial.","journal":"Nature communications"},{"date":"2026 Apr","pmid":"41885327","title":"Shared visits vs incident-to billing for pharmacy services.","journal":"Journal of managed care & specialty pharmacy"},{"date":"2026 Mar 25","pmid":"41879763","title":"The Oncology Care Model and Medicare Payments, Utilization, and Quality.","journal":"JAMA"},{"date":"2026 Mar 24","pmid":"41876647","title":"LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.","journal":"Nature medicine"},{"date":"2026 Mar 22","pmid":"41872005","title":"DNA damage induction and repair in peripheral blood mononuclear cells induced by internal ex vivo irradiation with β- and γ-emitting radionuclides.","journal":"Zeitschrift fur medizinische Physik"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MORPHINE GROUP","Rituximab","Ifosfamide","Ifex®","Etoposide"],"phase":"marketed","status":"active","brandName":"Part B","genericName":"Part B","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":2},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}